Harvard Bioscience
HBIO
71 hedge funds and large institutions have $74.7M invested in Harvard Bioscience in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 25 reducing their positions, and 17 closing their positions.
53% more capital invested
Capital invested by funds: $48.7M → $74.7M (+$26M)
0.05% less ownership
Funds ownership: 6.47% → 6.42% (-0.05%)
9% less funds holding
Funds holding: 78 → 71 (-7)
20% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 25
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Engine Capital Management
New York
|
+$4.16M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$2.28M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$2.11M |
| 4 |
HP
Harvey Partners
Tarrytown,
New York
|
+$1.85M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
-$1.44M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.18M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$1.18M |
| 4 |
Millennium Management
New York
|
-$1.05M |
| 5 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$1.01M |
HBIO Hedge Fund Activity: Q3 2019 in Review
71 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2019, worth a combined $74.7M — up 53% from $48.7M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of HBIO and 10 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 20 added.
The largest buyer was Engine Capital Management, adding an estimated $4.16M. The largest seller was Foundry Partners, exiting entirely with an estimated $1.44M sold.
- 71 institutional investors held Harvard Bioscience (HBIO) as of Q3 2019, down from 78 in Q2 2019.
- Funds reported $74.7M of Harvard Bioscience stock for Q3 2019, up 53% quarter-over-quarter.
- 10 funds opened new Harvard Bioscience positions in Q3 2019 and 17 closed out, a net change of -7 holders.
- The largest Harvard Bioscience buyer in Q3 2019 was Engine Capital Management, an estimated $4.16M added.
- The largest Harvard Bioscience seller in Q3 2019 was Foundry Partners, an estimated $1.44M sold.
Based on aggregated 13F filings for Q3 2019.